Y-Mabs falls to Serb
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
J&J gets a smouldering endorsement
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
